SCHEMBL4248560

SCHEMBL4248560

Cc1ccccc1-n1nc(-c2ccc(F)cc2)cc1Nc1ncccc1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K2 Q12851 3/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 5/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 4/20 0.44
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
HPGD P15428 1/20 0.44
NPC1 O15118 3/20 0.43
AHR P35869 1/20 0.43
MTOR P42345 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SYK P43405 3/20 0.41
CDC7 O00311 1/20 0.41
PLK4 O00444 1/20 0.41
DYRK3 O43781 1/20 0.41
ROCK2 O75116 1/20 0.41
PRKD3 O94806 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974452 0.93 LMNA (0.48) MAP4K2LMNAMAPTHTTRAB9A
SCHEMBL3973559 0.92 MAP4K2 (0.50) MAP4K2LMNAMAPTHTTRAB9A
SCHEMBL3973042 0.91 DHODH (0.51) LMNAMAPTRAB9ANPC1MEN1
SCHEMBL3979999 0.91 RAB9A (0.47) MAP4K2LMNAMAPTHTTRAB9A
SCHEMBL3974880 0.90 MAPT (0.42) LMNAMAPTRAB9AALDH1A1NPC1
SCHEMBL3975150 0.87 HTT (0.44) LMNAMAPTHTTRAB9AALDH1A1
SCHEMBL3973215 0.87 MAPT (0.41) LMNAMAPTHTTRAB9AALDH1A1
SCHEMBL3976033 0.84 ALDH1A1 (0.53) LMNAMAPTHTTRAB9AALDH1A1
SCHEMBL3861500 0.84 DHODH (0.50) LMNAMAPTRAB9AALDH1A1NPC1
SCHEMBL3977218 0.84 DHODH (0.50) LMNAMAPTHTTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP MAP4K2 1031/4885LMNA 3423/4885MAPT 3713/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP MAP4K2 1031/4885LMNA 3423/4885MAPT 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.